Paper - WANFANG MED ONLINE

You Position: Home > Paper

肝移植后新发糖尿病的危害、危险因素和防治措施

( views:268, downloads:52 )

Author:: No author available

Journal Title:: Chinese Journal of Organ Transplantation

Issue:: 12

DOI:: 10.3760/cma.j.issn.0254-1785.2012.12.016

Key Word:: No keyword available

Abstract：自1963年Starzl施行世界上首例肝移植,开启肝移植技术临床应用的序幕以来,随之相关的移植技术成为20世纪医学领域取得的重大进展之一,给许多终末期肝病患者带来治愈的希望,挽救了成千上万患者的生命,并且随着器官保存技术和免疫抑制剂的不断更新和发展,移植受者的预后更是有了显著改善.但是,肝移植后仍存在一些顽固的并发症始终困扰着我们,并且严重影响肝移植受者的生存状况.

Reference

[1]Lamoth F,Venetz JP,Leung-Ki EL,etc.Cytomegalovirus infection and new-onset post-transplant diabetes mellitus.[J].2008,22(2).
[2]Rogiers, X.,Vanholder, R.,Desideri, F.,etc.Hypomagnesemia and the risk of new-onset diabetes after liver transplantation[J].2010,16(11).
[3]Baldwin D,Villanueva G.Rosiglitazone therapy of posttransplant diabetes mellitus.[J].2005,80(10).
[4]Calmus Y,Roche B,Pageaux GP,etc.Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis c infection: an observational multicenter study.[J].2007,13(1).
[5]Pablo F, Mora.Post-transplantation diabetes mellitus.[J].2005,329(2).
[6]E J Gane.Diabetes mellitus following liver transplantation in patients with hepatitis C virus: risks and consequences.[J].2012,12(3).
[7]Wu Y,Boillot O,Levy G,etc.Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation.[J].2004,77(11).
[8]Aranda Narvaez JM,Santoyo Santoyo J,Sanchez Perez B.Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients.[J].2008,40(9).
[9]Faure, S,Bouyabrine, H,Assenat, E,etc.Long-Term Outcomes of Liver Transplantation: Diabetes Mellitus[J].2009,15(11S2).
[10]Heineck,I.,Gnatta,D.,Keitel,E.,etc.Use of Tacrolimus and the Development of Posttransplant Diabetes Mellitus: A Brazilian Single-Center, Observational Study[J].2010,42(2).
[11]Johnson JD,Ao Z,Ao P.Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets.[J].2009,18(8).
[12]I, Dresslerová,J, Vojácek.[Diabetes mellitus and ischemic heart disease].[J].2010,56(4).
[13]Uchigata Y,Ohta M,Babazono T,etc.Comparison of the prevalence of chronic kidney disease in Japanese patients with Type 1 and Type 2 diabetes.[J].2010,27(9).
[14]Hoppe Lotichius M,Weiler N,Zimmermann T,etc.Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial.[J].2010,90(12).
[15]Passer J,Bennett RG,Shivaswamy V,etc.Hyperglycemia induced by tacrolimus and sirolimus is reversible in normal sprague-dawley rats.[J].2010,37(3).
[16]Szabo,A.J.,Reusz,G.,Fekete,A.,etc.The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus[J].2012,13(1).
[17]Segal T,Webb E,Viner R,etc.Severe insulin resistance secondary to insulin antibodies: successful treatment with the immunosuppressant MMF.[J].2008,9(3 Pt.1).
[18]Zhao Y,Yersiz H,Busuttil RW,etc.Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation.[J].2006,6(8).
[19]Barbagallo M,Dominguez LJ.Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance[J].2007,458(1).
[20]Alves-Filho G,Mazzali M,Lalli CA,etc.Posttransplant diabetes mellitus: incidence and risk factors.[J].2008,40(3).
[21]Johnston GI,Strachan MW,Williamson RM,etc.Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study.[J].2011,34(5).
[22]Lewis C, Cantley.The phosphoinositide 3-kinase pathway.[J].2002,296(5573).
[23]Rahbar M,Lessan Pezeshki M,Seifi S.Posttransplant diabetes mellitus: incidence and risk factors.[J].2009,41(7).
[24]Marília B, Gomes,Roberta A, Cobas.Post-transplant diabetes mellitus.[J].2009,1(1).
[25]Valyi-Nagy T,Guzman G,Layden-Almer J,etc.Diabetes and hepatic oxidative damage are associated with hepatitis C progression after liver transplantation.[J].2007,84(5).
[26]Silbernagel,G.,Grammer,T.B.,M?rz,W.,etc.Duration of type 2 diabetes strongly predicts all-cause and cardiovascular mortality in people referred for coronary angiography[J].2012,221(2).
[27]Ali, Ghafari,Reza, PourAli,Nariman, Sepehrvand,etc.Post-transplantation diabetes mellitus; frequency and related risk factors: a single center study.[J].2010,21(5).
[28]Garcia Gil A,Xiol X,Figueras J,etc.Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study.[J].2006,44(4).
[29]Marchetti P.New-onset diabetes after liver transplantation: from pathogenesis to management.[J].2005,11(6).
[30]Gruessner A,Gruessner R,Humar A,etc.Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes.[J].2007,21(4).
[31]F, Tinti,A P, Mitterhofer,P, Muiesan.Liver transplantation: role of immunosuppression, renal dysfunction and cardiovascular risk factors.[J].2012,67(1).